Correlates of protection against influenza

Birkhauser Advances in Infectious Diseases

Volumn , Issue , 2011, Pages 199-222

  Montomoli, Emanuele ^a   Capecchi, Barbara ^b   Hoschler, Katja ^c  

^a UNIVERSITY OF SIENA   (Italy)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; IMMUNOGLOBULIN A; INACTIVATED VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LIVE VACCINE; NEUTRALIZING ANTIBODY; OSELTAMIVIR; RIMANTADINE; VIRUS ANTIBODY; VIRUS SIALIDASE; ZANAMIVIR;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CELLULAR IMMUNITY; COMPLEMENT HEMOLYSIS TEST; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; INFECTION PREVENTION; INFLUENZA; INFLUENZA A; INFLUENZA A (H2N2); INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS; MEDICAL ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; SERODIAGNOSIS; SEROEPIDEMIOLOGY; SEROLOGY; SINGLE RADIAL HEMOLYSIS; TREATMENT OUTCOME; VALIDITY; VIRUS IDENTIFICATION; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; WESTERN BLOTTING;

EID: 79960059839     PISSN: None     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-0346-0279-2_9     Document Type: Article

References (76)

1. Treanor J (2004) Influenza vaccine-outmaneuvering antigenic shift and drift. N Engl J Med 350:218-220
2. Webby RJ, Webster RG (2003) Are we ready for pandemic influenza? Science 302:1519-1522
3. Webby RJ, Swenson SL, Krauss SL, Gerrish PJ, Goyal SM et al (2000) Evolution of swine H3N2 influenza viruses in the United States. J Virol 74(18):8243-8251
4. Zhou NN, Senne DA, Landgraf JS, Swenson SL, Erickson G et al (1999) Genetic reassortment of avian, swine, and human influenza A viruses in American pigs. J Virol 73(10):8851-8856
5. Vincent AL, Ma W, Lager KM, Janke BH, Richt JA (2008) Swine influenza viruses: a North American perspective. Adv Virus Res 72:127-154
6. Barker WH, Mullooly JP (1980) Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 112:798-811
7. Barker WH (1986) Excess pneumonia and influenza-associated hospitalization during influenza epidemics in the United States, 1970-78. Am J Public Health 76:761-765
8. Dorrell L, Hassan I, Marshall S, Chakraverty P, Ong E (1997) Clinical and serological responses to an inactivated influenza vaccine in adults with HIV infection, diabetes, obstructive airways disease, elderly adults and healthy volunteers. Int J STD AIDS 8:776-779
9. Künzel W, Glathe H, Engelmann H, Van Hoecke C (1996) Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine 12:1108-1110
10. Stephenson I, Nicholson KG (2001) Influenza: vaccination and treatment. Eur Respir J 17:1282-1293
11. Betts RF, Treanor JJ (2000) Approaches to improved influenza vaccination. Vaccine 18 (16):1690-1695
12. Podda A (2001) The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19(17-19):2673-2680
13. Podda A, Del Giudice G (2003) MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2(2):197-203
14. Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A (2009) Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential phase I and phase II clinical trial. Vaccine 27(5):786-791
15. Ehrlich HJ, Müller M, Fritsch S, Zeitlinger M, Berezuk G, Löw-Baselli A, van der Velden MV, Pöllabauer EM, Maritsch F, Pavlova BG, Tambyah PA, Oh HM, Montomoli E, Kistner O, Noel Barrett P (2009) A cell culture (vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis 200(7):1113-1118
16. Couch RB, Kasel JA, Glezen WP, Cate TR, Six HR, Taber LH, Frank AL, Greenberg SB, Zahradnik JM, Keitel WA (1986) Influenza: its control in persons and populations. J Infect Dis 153:431-440
17. Beyer WE, Palache AM, de Jong JC, Osterhaus AD (2002) Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 20:1340-1353
18. Beyer WE, Palache AM, Lüchters G, Nauta J, Osterhaus AD (2004) Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res 103:125-132
19. EMEA (1996) Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96)
20. EMEA (2003) Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (CPMP/VEG/4717/03)
21. Hirst GK (1941) The agglutination of red cells by allantoic fluid of chick embryos infected with influenza virus. Science 94:22-23
22. Goodeve AC, Jennings R, Potter CW (1983) The use of the single radial haemolysis test for assessing antibody response and protective antibody levels in an influenza B vaccine study. J Biol Stand 11:289-296
23. Al-Khayatt R, Jennings R, Potter CW (1984) Interpretation of responses and protective levels of antibody against attenuated influenza A viruses using single radial haemolysis. J Hyg (Lond) 93:301-312
24. Hannoun C, Megas F, Piercy J (2004) Immunogenicity and protective efficacy of influenza vaccination. Virus Res 103:133-138
25. Hobson D, Curry RL, Beare AS, Ward-Gardner A (1972) The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 70:767-777
26. Wright PF, Bryant JD, Karzon DT (1980) Comparison of influenza B/Hong Kong virus infections among infants, children, and young adults. J Infect Dis 141:430-435
27. Monto AS, Maassab HF (1981) Ether treatment of type B influenza virus antigen for the haemagglutination inhibition test. J Clin Microbiol 13:54-57
28. Kendal AP, Cate TR (1983) Increased sensitivity and reduced specificity of haemagglutination inhibition tests with ether-treated influenza B/Singapore/222/79. J Clin Microbiol 18:930-934
29. Palmer DF, Coleman MT, Dowdle WR, Schild GC (1975) Advanced laboratory techniques for influenza diagnosis. Immunology series, procedural guide 6. US Department of Health, Education, and Welfare; Public Health Service; Center for Disease Control, 34
30. Hinshaw VS, Webster RG, Easterday BC, Bean WJ Jr (1981) Replication of avian influenza A viruses in mammals. Infect Immun 34:354-361
31. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, Fukuda K, Cox NJ, Katz JM (1999) Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37:937-943
32. Stephenson I, Wood JM, Nicholson KG, Zambon MC (2003) Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. J Med Virol 70:391-398
33. Profeta ML, Palladino G (1986) Serological evidence of human infections with avian influenza viruses. Arch Virol 90:355-360
34. Schild GC, Pereira MS, Chakraverty P (1975) Single-radial-hemolysis: a new method for the assay of antibody to influenza haemagglutinin. Applications for diagnosis and seroepidemiologic surveillance of influenza. Bull World Health Organ 52:43-50
35. Mumford J, Wood J (1993) WHO/OIE meeting: consultation on newly emerging strains of equine influenza. 18-19 May 1992, Animal Health Trust, Newmarket, Suffolk, UK. Vaccine 11:1172-1175
36. Wood JM, Gaines-Das RE, Taylor J, Chakraverty P (1994) Comparison of influenza serological techniques by international collaborative study. Vaccine 12:167-174
37. Wood JM, Melzack D, Newman RW, Major DL, Zambon M, Nicholson KG, Podda A (2001) A single radial haemolysis assay for antibody to H5 haemagglutinin. Int Congr Ser 1219:761-766
38. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357:1937-1943
39. Gross PA, Barry DW, D'Esopo N (1976) Influenza immunization in chronic bronchitis: local and systemic immune response. Am Rev Respir Dis 114:305-313
40. Benne CA, Harmsen M, de Jong JC, Kraaijeveld CA (1994) Neutralization enzyme immunoassay for influenza virus. J Clin Microbiol 32:987-990
41. Harmon MW, Rota PA, Walls HH, Kendal AP (1988) Antibody response in humans to influenza virus type B host cell-derived variants after vaccination with standard (egg-derived) vaccine or natural infection. J Clin Microbiol 26:333-337
42. Fodor E, Devenish L, Engelhardt OG et al (1999) Rescue of influenza A virus from recombinant DNA. J Virol 73:9679-9682
43. Subbarao K, Chen H, Swayne D et al (2003) Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305:192-200
44. Neumann G, Fujii K, Kino Y, Kawaoka Y (2005) An improved reverse genetics system for influenza A virus generation and its implications for vaccine production. Proc Natl Acad Sci USA 102:16825-16829
45. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354:1343-1351
46. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Höschler K, Zambon MC (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367:1657-1664
47. Katz JM, Lim W, Bridges CB et al (1999) Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis 180:1763-1770
48. Kayali G, Setterquist SF, Capuano AW, Myers KP, Gill JS, Gray GC (2008) Testing human sera for antibodies against avian influenza viruses: horse RBC haemagglutination inhibition vs. microneutralization assays. J Clin Virol 43(1):73-78
49. Myers KP, Setterquist SF, Capuano AW, Gray GC (2007) Infection due to 3 avian influenza subtypes in United States veterinarians. Clin Infect Dis 45(1):4-9
50. Frank AL, Puck J, Hughes BJ, Cate TR (1980) Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement. J Clin Microbiol 12:426-432
51. Okuno Y, Tanaka K, Baba K, Maeda A, Kunita N, Ueda S (1990) Rapid focus reduction neutralization test of influenza A and B viruses in microtitre system. J Clin Microbiol 28:1308-1313
52. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC (2004) Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 103:91-95
53. Govorkova EA, Smirnov Yu A (1997) Cross-protection of mice immunized with different influenza A (H2) strains and challenged with viruses of the same HA subtype. Acta Virol 41:251-257
54. Temperton NJ, Hoschler K, Major D, Nicolson C, Manvell R, Hien VM, Ha DQ, de Jong M, Zambon MC, Takeuchi Y, Weiss RA (2007) A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respi Viruses 1:105-112
55. Kong WP, Hood C, Yang ZY, Wei CJ, Xu L, García-Sastre A, Tumpey TM, Nabel GJ (2006) Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. Proc Natl Acad Sci USA 103(43):15987-15991
56. Wang W, Butler EN, Veguilla V, Vassell R, Thomas JT, Moos M Jr, Ye Z, Hancock K, Weiss CD (2008) Establishment of retroviral pseudotypes with influenza haemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J Virol Methods 153(2):111-119
57. Alberini I, Del Tordello B, Fasolo A, Temperton NJ, Galli G, Gentile C, Montomoli E, Hilbert AK, Banzhoff A, Del Giudice G, Donnelly J, Rappuoli R, Capecchi B (2009) Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine 27(43):5998-6003
58. Su CY, Wang SY, Shie JJ, Jeng KS, Temperton NJ, Fang JM, Wong CH, Cheng YS (2008) In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of haemagglutinin-pseudotyped viruses. Antivir Res 79:199-205
59. Qiu M, Fang F, Chen Y et al (2006) Protection against avian influenza H9N2 virus challenge by immunization with haemagglutinin- or neuraminidase-expressing DNA in BALB/c mice. Biochem Biophys Res Commun 343:1124-1131
60. Johansson BE, Bucher DJ, Kilbourne ED (1989) Purified influenza virus haemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol 63:1239-1246
61. Kilbourne ED, Pokorny BA, Johansson B et al (2004) Protection of mice with recombinant influenza virus neuraminidase. J Infect Dis 189:459-461
62. Chen Z, Kadowaki S, Hagiwara Y et al (2000) Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 18:3214-3222
63. Monto AS, Kendal AP (1973) Effect of neuraminidase antibody on Hong Kong influenza. Lancet 1:623-625
64. Tamura M, Webster RG, Ennis FA (1994) Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses. J Virol 68:3499-3504
65. Sandbulte MR, Jimenez GS, Boon AC et al (2007) Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 4:e59
66. Gioia C, Castilletti C, Tempestilli M et al (2008) Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis 14:121-128
67. Webster RG, Campbell CH (1972) An inhibition test for identifying the neuraminidase antigen on influenza viruses. Avian Dis 16:1057-1066
68. Clements ML, Betts RF, Tierney EL, Murphy BR (1986) Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 24:157-160
69. Schulman JL, Kilbourne ED (1969) Independent variation in nature of haemagglutinin and neuraminidase antigens of influenza virus: distinctiveness of haemagglutinin antigen of Hong Kong-68 virus. Proc Natl Acad Sci USA 63:326-333
70. Burlington DB, Clements ML, Meiklejohn G, Phelan M, Murphy BR (1983) Haemagglutininspecific antibody responses in immunoglobulin G, A, andMisotypes as measured by enzymelinked immunosorbent assay after primary or secondary infection of humans with influenza A virus. Infect Immun 41:540-545
71. Murphy BR, Phelan MA, Nelson DL et al (1981) Haemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol 13:554-560
72. Stelzer-Braid S, Wong B, Robertson P et al (2008) A commercial ELISA detects high levels of human H5 antibody but cross-reacts with influenza A antibodies. J Clin Virol 43:241-243
73. Doller G, Schuy W, Tjhen KY, Stekeler B, Gerth HJ (1992) Direct detection of influenza virus antigen in nasopharyngeal specimens by direct enzyme immunoassay in comparison with quantitating virus shedding. J Clin Microbiol 30:866-869
74. Wood JM, Robertson JS (2004) From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2:842-847
75. Hoffmann E, Krauss S, Perez D, Webby R, Webster RG (2002) Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 20:3165-3170
76. Temperton NJ, Wright E (2009) Retroviral pseudotypes. Encyclopedia of life sciences (ELS). Wiley, Chichester. doi:10.1002/9780470015902.a0021549